Literature DB >> 32665357

The Synthetic Small Molecule FL3 Combats Intestinal Tumorigenesis via Axin1-Mediated Inhibition of Wnt/β-Catenin Signaling.

Dakota N Jackson1, Kibrom M Alula2, Yaritza Delgado-Deida2, Redouane Tabti3, Kevin Turner4, Xuan Wang1, K Venuprasad4, Rhonda F Souza1, Laurent Désaubry3, Arianne L Theiss5,2.   

Abstract

Colorectal cancer exhibits aberrant activation of Wnt/β-catenin signaling. Many inhibitors of the Wnt/β-catenin pathway have been tested for Wnt-dependent cancers including colorectal cancer, but are unsuccessful due to severe adverse reactions. FL3 is a synthetic derivative of natural products called flavaglines, which exhibit anti-inflammatory and cytoprotective properties in intestinal epithelial cells, but has not been previously tested in cell or preclinical models of intestinal tumorigenesis. In vitro studies suggest that flavaglines target prohibitin 1 (PHB1) as a ligand, but this has not been established in the intestine. PHB1 is a highly conserved protein with diverse functions that depend on its posttranslational modifications and subcellular localization. Here, we demonstrate that FL3 combats intestinal tumorigenesis in the azoxymethane-dextran sodium sulfate and ApcMin/+ mouse models and in human colorectal cancer tumor organoids (tumoroids) by inhibiting Wnt/β-catenin signaling via induction of Axin1 expression. FL3 exhibited no change in cell viability in normal intestinal epithelial cells or human matched-normal colonoids. FL3 response was diminished in colorectal cancer cell lines and human colorectal cancer tumoroids harboring a mutation at S45 of β-catenin. PHB1 deficiency in mice or in human colorectal cancer tumoroids abolished FL3-induced expression of Axin1 and drove tumoroid death. In colorectal cancer cells, FL3 treatment blocked phosphorylation of PHB1 at Thr258, resulting in its nuclear translocation and binding to the Axin1 promoter. These results suggest that FL3 inhibits Wnt/β-catenin signaling via PHB1-dependent activation of Axin1. FL3, therefore, represents a novel compound that combats Wnt pathway-dependent cancers, such as colorectal cancer. SIGNIFICANCE: Targeting of PHB1 by FL3 provides a novel mechanism to combat Wnt-driven cancers, with limited intestinal toxicity. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/17/3519/F1.large.jpg. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32665357      PMCID: PMC7484901          DOI: 10.1158/0008-5472.CAN-20-0216

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Proteomic profiling of a mouse model of acute intestinal Apc deletion leads to identification of potential novel biomarkers of human colorectal cancer (CRC).

Authors:  Abeer Hammoudi; Fei Song; Karen R Reed; Rosalind E Jenkins; Valerie S Meniel; Alastair J M Watson; D Mark Pritchard; Alan R Clarke; John R Jenkins
Journal:  Biochem Biophys Res Commun       Date:  2013-08-31       Impact factor: 3.575

2.  Identification of prohibitin and prohibiton as novel factors binding to the p53 induced gene 3 (PIG3) promoter (TGYCC)(15) motif.

Authors:  Xiaoxiang Guan; Zhensheng Liu; Luo Wang; David G Johnson; Qingyi Wei
Journal:  Biochem Biophys Res Commun       Date:  2014-01-03       Impact factor: 3.575

3.  A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury.

Authors:  T Fahrig; I Gerlach; E Horváth
Journal:  Mol Pharmacol       Date:  2005-02-16       Impact factor: 4.436

Review 4.  Complexity of the Wnt/β‑catenin pathway: Searching for an activation model.

Authors:  Giovane G Tortelote; Renata R Reis; Fabio de Almeida Mendes; Jose Garcia Abreu
Journal:  Cell Signal       Date:  2017-08-26       Impact factor: 4.315

Review 5.  TP53 mutation in colorectal cancer.

Authors:  Barry Iacopetta
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

6.  Proteomics analysis of mitochondrial proteins reveals overexpression of a mitochondrial protein chaperon, prohibitin, in cells expressing hepatitis C virus core protein.

Authors:  Takeya Tsutsumi; Mami Matsuda; Hideki Aizaki; Kyoji Moriya; Hideyuki Miyoshi; Hajime Fujie; Yoshizumi Shintani; Hiroshi Yotsuyanagi; Tatsuo Miyamura; Tetsuro Suzuki; Kazuhiko Koike
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

7.  Structural organization of mitochondrial human complex I: role of the ND4 and ND5 mitochondria-encoded subunits and interaction with prohibitin.

Authors:  Ingrid Bourges; Claire Ramus; Bénédicte Mousson de Camaret; Réjane Beugnot; Claire Remacle; Pierre Cardol; Götz Hofhaus; Jean-Paul Issartel
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

8.  Aberrant gene methylation in non-neoplastic mucosa as a predictive marker of ulcerative colitis-associated CRC.

Authors:  Marco Scarpa; Melania Scarpa; Ignazio Castagliuolo; Francesca Erroi; Andromachi Kotsafti; Silvia Basato; Paola Brun; Renata D'Incà; Massimo Rugge; Imerio Angriman; Carlo Castoro
Journal:  Oncotarget       Date:  2016-03-01

9.  FL3, a Synthetic Flavagline and Ligand of Prohibitins, Protects Cardiomyocytes via STAT3 from Doxorubicin Toxicity.

Authors:  Rehana Qureshi; Onur Yildirim; Adeline Gasser; Christine Basmadjian; Qian Zhao; Jean-Philippe Wilmet; Laurent Désaubry; Canan G Nebigil
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

Review 10.  Prohibitin ligands in cell death and survival: mode of action and therapeutic potential.

Authors:  Frédéric Thuaud; Nigel Ribeiro; Canan G Nebigil; Laurent Désaubry
Journal:  Chem Biol       Date:  2013-03-21
View more
  4 in total

Review 1.  SFPH proteins as therapeutic targets for a myriad of diseases.

Authors:  Dong Wang; Redouane Tabti; Sabria Elderwish; Amel Djehal; Nora Chouha; Franck Pinot; Peng Yu; Canan G Nebigil; Laurent Désaubry
Journal:  Bioorg Med Chem Lett       Date:  2020-10-06       Impact factor: 2.823

2.  Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination.

Authors:  Zhiguo Wang; Conghua Lu; Kejun Zhang; Caiyu Lin; Fang Wu; Xiaolin Tang; Di Wu; Yuanyao Dou; Rui Han; Yubo Wang; Chao Hou; Qin Ouyang; Mingxia Feng; Yong He; Li Li
Journal:  Front Mol Biosci       Date:  2022-02-23

3.  The E3 Ubiquitin Ligase TRIM11 Facilitates Gastric Cancer Progression by Activating the Wnt/β-Catenin Pathway via Destabilizing Axin1 Protein.

Authors:  Ling Zhou; Heng Wang; Min Zhong; Zhi Fang; Yi Le; Fengting Nie; Juanjuan Zhou; Jianping Xiong; Xiaojun Xiang; Ziling Fang
Journal:  J Oncol       Date:  2022-02-21       Impact factor: 4.375

Review 4.  Prohibitins: A Key Link between Mitochondria and Nervous System Diseases.

Authors:  Tianlin Jiang; Jiahua Wang; Chao Li; Guiyun Cao; Xiaohong Wang
Journal:  Oxid Med Cell Longev       Date:  2022-07-08       Impact factor: 7.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.